The pharma industry is just months away from laying bare its relationships with doctors in Europe, revealing for the first time the names of doctors, how much individual pharma companies have paid them, and for what.
From 30 June 2016, all pharmaceutical companies will be required to publish payments made in the previous year to doctors, nurses, and other healthcare professionals (HCPs), and identify them by name wherever possible. The new rules will also include payments to hospitals and other healthcare organisations (HCOs) across 33 European countries.
Not surprisingly, there are some worries about what will happen in June: will every pharma company disclose its data on time? Will doctors protest against having their details published? And, most importantly, will disclosure actually stoke public suspicions about inappropriate influence, rather than allay fears?
One thing is clear – across a continent with such diverse cultures and practices, the patterns and levels of disclosure will be far from uniform.
To read the article by Andrew McConaghie